Transcriptome alteration in Nrf2 mutant developing oligodendrocytes treated with interferon gamma and thapsigargin in comparison with wild-type developing oligodendrocytes treated with interferon gamma and thapsigargin
RNA-seq (gene expression) · mouse · 50 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 50 samples: 50 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE161562_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA678719 and SRA study SRP292747. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 50 sample titles: 50 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM4910150 Untreated WT Developing Oligodendrocytes [HS-1]
- GSM4910151 IFN gamma-treated WT Developing Oligodendrocytes [HS-2]
- GSM4910152 Thapsigargin-treated WT Developing Oligodendrocytes [HS-3]
- GSM4910153 Untreated WT Developing Oligodendrocytes [HS-4]
- GSM4910154 Thapsigargin-treated WT Developing Oligodendrocytes [HS-5]
- GSM4910155 IFN gamma-treated WT Developing Oligodendrocytes [HS-6]
- GSM4910156 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-7]
- GSM4910157 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-8]
- GSM4910158 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-9]
- GSM4910159 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-10]
- GSM4910160 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-11]
- GSM4910161 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-12]
- GSM4910162 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-13]
- GSM4910163 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-14]
- GSM4910164 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-15]
- GSM4910165 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-16]
- GSM4910166 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-17]
- GSM4910167 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-18]
- GSM4910168 Untreated WT Developing Oligodendrocytes [HS-19]
- GSM4910169 Thapsigargin-treated WT Developing Oligodendrocytes [HS-20]
- GSM4910170 IFN gamma-treated WT Developing Oligodendrocytes [HS-21]
- GSM4910171 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-22]
- GSM4910172 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-23]
- GSM4910173 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-24]
- GSM4910174 IFN gamma-treated WT Developing Oligodendrocytes [HS-25]
- GSM4910175 Untreated WT Developing Oligodendrocytes [HS-26]
- GSM4910176 Thapsigargin-treated WT Developing Oligodendrocytes [HS-27]
- GSM4910177 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-28]
- GSM4910178 Thapsigargin-treated Nrf2-mutant Developing Oligodendrocytes [HS-29]
- GSM4910179 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-30]
- GSM4910180 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-31]
- GSM4910181 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-32]
- GSM4910182 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-33]
- GSM4910183 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-34]
- GSM4910184 IFN gamma-treated WT Developing Oligodendrocytes [HS-35]
- GSM4910185 Untreated WT Developing Oligodendrocytes [HS-36]
- GSM4910186 Untreated WT Developing Oligodendrocytes [HS-37]
- GSM4910187 IFN gamma-treated WT Developing Oligodendrocytes [HS-38]
- GSM4910188 IFN gamma-treated Nrf2-mutant Developing Oligodendrocytes [HS-39]
- GSM4910189 Untreated Nrf2-mutant Developing Oligodendrocytes [HS-40]
+ 10 more — browse all 50 samples with per-sample file links →
- GSE161561 Transcriptome alteration in wild-type developing oligodendrocytes treated with interferon gamma and thapsigargin in comparison with untreated wild-type developing oligodendrocytes 40 samples shares oligodendrocytes, thapsigargin, alteration, developing, interferon, comparison, wild-type
- GSE299332 NRF2 Activation in Cancer Cells Suppresses Immune Infiltration into Tumor Microenvironment 28 samples shares nrf2
- GSE255927 Differential squamous cell fates elicited by NRF2 gain-of-function versus KEAP1 loss-of-function 25 samples shares nrf2
- GSE266962 Targeting Immunoproteasome in Macrophages Suppresses M1 Polarization and Ameliorates Experimental Emphysema via Activating NRF1 and NRF2-P62 Axis 24 samples shares nrf2
- GSE301971 Modelling HNSCC in mice with hyperactivated NRF2 pathway 22 samples shares nrf2
- GSE299877 N-acetyl-L-cysteine ethyl ester (NACET) induces the transcription factor NRF2 in the retina and prevents its aging and diabetic retinopathy. [III] 20 samples shares nrf2
- GSE299879 N-acetyl-L-cysteine ethyl ester (NACET) induces the transcription factor NRF2 in the retina and prevents its aging and diabetic retinopathy. [IV] 18 samples shares nrf2
- GSE266023 Nrf2-mediated chromatin activation of hyperosmotic response genes attenuates heat-induced renal injury [RNA-seq] 16 samples shares nrf2
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.